WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205840
Description: GDC-0425, also known as RG7602. is an oral, selective Chk1 inhibitor. GDC-0425 enhances gemcitabine (gem) efficacy in tumor xenograft models. Greater chemopotentiation is observed in cancer cell lines lacking p53 activity. GDC-0425 blocks the function of a protein called checkpoint kinase 1 (Chk1). GDC-0425 was safe and yielded responses in patients with a variety of cancer types, including triple-negative breast cancer, melanoma, and cancer of unknown primary, according to data from a phase I clinical trial presented at the AACR Annual Meeting 2015, held April 18-22.
MedKoo Cat#: 205840
Chemical Formula: C18H19N5O
Exact Mass: 321.159
Molecular Weight: 321.384
Elemental Analysis: C, 67.27; H, 5.96; N, 21.79; O, 4.98
Synonym: GDC0425; GDC-0425; GDC 0425; RG7602; RG-7602; RG 7602.
IUPAC/Chemical Name: 5-((1-ethylpiperidin-4-yl)oxy)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile
InChi Key: XEZLBMHDUXSICI-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H19N5O/c1-2-23-8-5-12(6-9-23)24-17-14(10-19)21-11-15-16(17)13-4-3-7-20-18(13)22-15/h3-4,7,11-12H,2,5-6,8-9H2,1H3,(H,20,22)
SMILES Code: N#CC1=NC=C2C(C3=CC=CN=C3N2)=C1OC4CCN(CC)CC4
1: Ding X, Chen Y, Sahasranaman S, Shi Y, McKnight J, Dean B. A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma. Biomed Chromatogr. 2016 Jun 1. doi: 10.1002/bmc.3775. [Epub ahead of print] PubMed PMID: 27245274.
2. Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425. Andreas Stumpf*†, Zhigang Ken Cheng†, Brian Wong†, Mark Reynolds†, Remy Angelaud†, James Girotti‡, Alan Deese‡, Christine Gu‡, and Lewis Gazzard. †Small Molecule Process Chemistry, ‡Small Molecule Analytical Chemistry, §Department of Discovery Chemistry, Genentech, A member of the Roche Group, 1 DNA Way, South San Francisco, California 94080, United States Org. Process Res. Dev., 2015, 19 (6), pp 661–672. DOI: 10.1021/acs.oprd.5b00105